Compare Stocks: FATE, GLUE, KURA, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.42 -0.6%	$2.62	$0.93 ▼ $3.23	$289.37M	2.54	2.57 million shs	809,553 shs
GLUE Monte Rosa Therapeutics	$14.16 -1.0%	$19.49	$4.78 ▼ $25.77	$1.20B	1.5	1.36 million shs	515,613 shs
JANX Janux Therapeutics	$19.72 +4.4%	$16.27	$12.12 ▼ $35.34	$1.20B	2.53	1.11 million shs	928,275 shs
KURA Kura Oncology	$12.88 -0.1%	$10.96	$7.36 ▼ $13.90	$1.15B	0.38	1.65 million shs	675,878 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+1.67%	-4.71%	-0.82%	+9.46%	+133.65%
GLUE Monte Rosa Therapeutics	+2.65%	-1.72%	-13.38%	-18.65%	+198.13%
JANX Janux Therapeutics	+3.68%	+1.12%	+24.52%	+39.00%	-16.86%
KURA Kura Oncology	+1.90%	-5.15%	+43.06%	+48.93%	+63.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.42 -0.6%	$2.62	$0.93 ▼ $3.23	$289.37M	2.54	2.57 million shs	809,553 shs
GLUE Monte Rosa Therapeutics	$14.16 -1.0%	$19.49	$4.78 ▼ $25.77	$1.20B	1.5	1.36 million shs	515,613 shs
JANX Janux Therapeutics	$19.72 +4.4%	$16.27	$12.12 ▼ $35.34	$1.20B	2.53	1.11 million shs	928,275 shs
KURA Kura Oncology	$12.88 -0.1%	$10.96	$7.36 ▼ $13.90	$1.15B	0.38	1.65 million shs	675,878 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+1.67%	-4.71%	-0.82%	+9.46%	+133.65%
GLUE Monte Rosa Therapeutics	+2.65%	-1.72%	-13.38%	-18.65%	+198.13%
JANX Janux Therapeutics	+3.68%	+1.12%	+24.52%	+39.00%	-16.86%
KURA Kura Oncology	+1.90%	-5.15%	+43.06%	+48.93%	+63.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	144.31% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	101.27% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	84.89% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.40	97.20% Upside

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	43.51	N/A	N/A	$1.28 per share	1.89
GLUE Monte Rosa Therapeutics	$123.67M	9.77	N/A	N/A	$5.71 per share	2.48
JANX Janux Therapeutics	$10M	120.57	N/A	N/A	$15.18 per share	1.30
KURA Kura Oncology	$77.23M	14.84	N/A	N/A	$0.54 per share	23.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest FATE, GLUE, KURA, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
JANX Janux Therapeutics	N/A	16.35	16.35
KURA Kura Oncology	0.12	4.73	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
GLUE Monte Rosa Therapeutics	79.96%
JANX Janux Therapeutics	75.39%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
GLUE Monte Rosa Therapeutics	6.40%
JANX Janux Therapeutics	7.90%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable

FATE, GLUE, KURA, and JANX Headlines

Recent News About These Companies

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

September 1 at 10:06 AM | zacks.com

Kura Oncology to Participate in Three Investor Conferences in September

September 1 at 7:15 AM | globenewswire.com

Hsbc Holdings PLC Invests $1.05 Million in Kura Oncology, Inc. $KURA

September 1 at 3:59 AM | marketbeat.com

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?

August 31 at 1:01 PM | zacks.com

Man Group plc Buys New Shares in Kura Oncology, Inc. $KURA

August 31 at 5:11 AM | marketbeat.com

Deutsche Bank AG Takes Position in Kura Oncology, Inc. $KURA

August 31 at 3:38 AM | marketbeat.com

BlackRock Inc. Takes $115.29 Million Position in Kura Oncology, Inc. $KURA

August 30 at 3:29 AM | marketbeat.com

Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase

August 27, 2026 | msn.com

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

August 27, 2026 | zacks.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Kura Oncology, Inc. $KURA

August 27, 2026 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Sets New 1-Year High After Insider Buying Activity

August 27, 2026 | americanbankingnews.com

Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects

August 26, 2026 | seekingalpha.com

Kura Oncology shares jump after CEO buys $1.24 million of stock

August 26, 2026 | msn.com

kura oncology inc. - KURA

August 26, 2026 | foxbusiness.com

Kura's CEO Just Wrote Two Real Checks. The Stock Noticed.

August 26, 2026 | moneymorning.comM

Citizens Jmp Reiterates "Market Outperform" Rating for Kura Oncology (NASDAQ:KURA)

August 26, 2026 | americanbankingnews.com

KURA stock hits fresh 52-week high as CEO buys more shares — retail wonders if Wilson is following Moderna CEO’s playbook

August 25, 2026 | msn.com

Kura Oncology Earnings Call Highlights COMZIFTI Momentum

August 25, 2026 | theglobeandmail.com

Stocks making the biggest moves midday: Dick's Sporting Goods, Marvell, AMD, Kura Oncology & more

August 25, 2026 | cnbc.com

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

August 25, 2026 | fool.com

The $1.24 billion reason why Kura Oncology stock is up today

August 25, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and JANX Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.42 -0.02 (-0.62%)

As of 01:17 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$14.16 -0.15 (-1.05%)

As of 01:18 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$19.72 +0.83 (+4.40%)

As of 01:18 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Kura Oncology NASDAQ:KURA

$12.88 -0.01 (-0.08%)

As of 01:18 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, GLUE, KURA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, GLUE, KURA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and JANX Company Descriptions

Fate Therapeutics NASDAQ:FATE

Monte Rosa Therapeutics NASDAQ:GLUE

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, GLUE, KURA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, GLUE, KURA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, GLUE, KURA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, GLUE, KURA, and JANX Company Descriptions

Fate Therapeutics NASDAQ:FATE

Monte Rosa Therapeutics NASDAQ:GLUE

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools